From science to clinical impact

Mesenchymal stromal cells (MSCs) were first described in the late 1960s and have since been intensively studied both in the laboratories and clinical trials.

MSCs have immune-modulatory, anti-inflammatory and regenerative properties. Both autologous and allogeneic MSCs have been used for the treatment of hematological, inflammatory and autoimmune diseases for the last 20 years.

The cells can be isolated from various tissues including bone marrow, adipose tissue, umbilical cord tissue and cord blood. MSCs can be induced to differentiate into osteocytes, chondrocytes and adipocytes (bone, cartilage and fat cells, respectively), but it is their immunomodulatory characteristics and potential to interact with the immune cells of the recipient that makes them unique in treatment of multiple diseases.

Our product – how it works

The safety and efficacy profile of MSCs differ depending on cell source, manufacturing protocols, administration procedures, biology of disease to be treated and the biology of each individual patient.

StromaBio´s MSC product are isolated from bone marrow of healthy donors. Isolated cells are expanded in the laboratory under strict sterile conditions and tested for purity and functionality before being released, following the legislation for manufacturing of sterile advanced medicinal products.The product is manufactured in Sweden. The MSC product is administered in the ideal way depending on indication. 

Strong IP and scientific position lay foundation for clinical path ahead

Many world-renowned scientists and clinicians, centered around Prof. Katarina Leblanc and the MSC platform she established, have run pre-clinical and clinical research for more than ten years to optimize protocols and processes resulting in exceptional MSC quality.  StromaBio  is now taking this product further, developing it into the format needed to reach market authorization.

Our product is well patented, either through innovative processing or in combination with administration protocols. The outcomes of our research are compelling and lay a strong foundation for our future clinical path.